Alzheimer Disease clinical trials

The registry lists 3,967 studies for Alzheimer Disease across more than 10 countries. 928 are recruiting or about to start. 3,074 of them are mainly about Alzheimer Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 4,339 studies for Alzheimer Disease. How that becomes 3,963 here

This page counts the studies the registry files under Alzheimer Disease, and those it files under no condition that list Alzheimer Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

4,339Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−77List Alzheimer Disease as a condition, but the registry did not file them under itMost often written as “Alzheimer s Disease” (17), “Mild Alzheimer's Disease” (8), and “Prodromal Alzheimer's Disease” (7). The registry filed them under other conditions only, most often Cognitive Dysfunction (29) and Dementia (15).
−299Match it another way188 name it in the title, 17 in a keyword, and 94 by a synonym or other text the search reads.
3,963The count on this page78 of them list Alzheimer Disease in their own words; the registry filed them under no condition.

Get an email when these change. Save the Alzheimer Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 2,140
Recruiting: 642
Status unknown: 325
Terminated: 300
Not yet recruiting: 210
Active, not recruiting: 166

Phase

Phase 2: 730
Phase 1: 575
Phase 3: 359
Phase 4: 139
Early Phase 1: 63

Where

United States: 1,939
France: 438
Canada: 320
Spain: 278
United Kingdom: 261
China: 260

Who runs them

Pfizer (63) · Eli Lilly and Company (57) · Avid Radiopharmaceuticals (42) · National Institute on Aging (NIA) (42) · Indiana University (32) · Wyeth is now a wholly owned subsidiary of Pfizer (32) · GlaxoSmithKline (31) · Merck Sharp & Dohme LLC (31)

What is being tested here

Drugs under test in Alzheimer Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Donanemab	7	7	15
Xanomeline	7	7	7
Trospium	7	7	7
Flortaucipir	4	4	22
Semaglutide	4	2	6
Lecanemab	3	3	8
Florzolotau F-18	3	3	8
Levetiracetam	3	1	8
Acoramidis	3	5	7
Daridorexant	3	0	4

Drug classes tested here Antimuscarinics 7 open · Cholinesterase inhibitors 4 open · GLP-1 receptor agonists 4 open · Stimulants 3 open · Reverse transcriptase inhibitors 2 open

Coming up

71phase 3 studies under way

343studies finish main data collection within a year12 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) · Phase 3 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Dec 2026Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function · Phase 3 · JYAMS PET Research & Development Limited
Dec 2026A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) · Phase 3 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Dec 2026Biomarker Exploration in Aging, Cognition and Neurodegeneration · Phase 3 · University of California, Irvine
Dec 2026A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease · Phase 3 · Eisai Inc.
Jan 2027Clinical Analgesic Management in Dementia · Phase 3 · Xuanwu Hospital, Beijing
Jan 2027A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease · Phase 3 · Shanghai Jiao Tong University School of Medicine
Apr 2027Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD. · Phase 3 · JYAMS PET Research & Development Limited
May 2027Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia · Phase 3 · Bigespas LTD
Jul 2027Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A) · Phase 3 · Danyang Huichuang Medical Equipment Co., Ltd.

Who these studies take

Of the 642 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 55 (9%) stop at 75 or younger. 34 (5%) take children under 18. 9 (1%) are for women only and 3 (<1%) for men only; 284 (44%) take healthy volunteers.

Recruiting studies that take each age, of 642
Age	Women	Men
10	30 (5%)	30 (5%)
18	198 (31%)	192 (30%)
30	220 (34%)	215 (33%)
40	265 (41%)	259 (40%)
50	422 (66%)	417 (65%)
65	622 (97%)	616 (96%)
75	608 (95%)	603 (94%)
85	516 (80%)	510 (79%)

Across all 3,967 studies, recruiting or not: 10% stop at 75 or younger and 6% at 65; 7% take children; 1% are for women only and 2% for men only; 37% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Alzheimer Disease studies take

Of 257 phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	18 mo7–39 · 234 studies	12 mo6–23 · 161 studies	44 mo18–57 · 73 studies
Phase 1/2	45 mo21–63 · 62 studies	—	41 mo21–63 · 35 studies
Phase 2	37 mo21–58 · 257 studies	26 mo17–39 · 130 studies	54 mo37–69 · 127 studies
Phase 2/3	52 mo33–59 · 28 studies	—	—
Phase 3	47 mo28–73 · 101 studies	42 mo28–61 · 75 studies	—
Phase 4	47 mo27–67 · 41 studies	—	—
Interventional, no phase	29 mo15–51 · 959 studies	18 mo11–40 · 77 studies	30 mo15–51 · 882 studies
Observational	67 mo35–171 · 405 studies	34 mo20–63 · 41 studies	81 mo39–203 · 364 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out